Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History GLUE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics GLUE

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Monte Rosa Therapeutics Inc

GLUE
Current price
5.90 USD +0.26 USD (+4.61%)
Last closed 5.23 USD
ISIN US61225M1027
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 323 541 568 USD
Yield for 12 month +34.40 %
1Y
3Y
5Y
10Y
15Y
GLUE
21.11.2021 - 28.11.2021

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1b and the NLRP3 inflammasome. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd. to discover and develop MGDs against targets in cancer and neurological diseases. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts. Address: 321 Harrison Avenue, Boston, MA, United States, 02118

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

15.75 USD

P/E Ratio

43.83

Dividend Yield

Financials GLUE

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures GLUE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+75 622 000 USD

Last Year

Current Quarter

+84 929 000 USD

Last Quarter

+60 647 000 USD

Current Year

+67 501 000 USD

Last Year

-6 222 000 USD

Current Quarter

+84 929 000 USD

Last Quarter

+58 586 000 USD
EBITDA 6 143 000 USD
Operating Margin TTM 51.85 %
Price to Earnings 43.83
Return On Assets TTM -0.40 %
PEG Ratio
Return On Equity TTM 2.88 %
Wall Street Target Price 15.75 USD
Revenue TTM 159 487 008 USD
Book Value 4.47 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 7 882.00 %
Dividend Yield
Gross Profit TTM 46 624 000 USD
Earnings per share 0.12 USD
Diluted Eps TTM 0.12 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin 3.86 %

Stock Valuation GLUE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 43.83
Forward PE 11.83
Enterprise Value Revenue 0.26
Price Sales TTM 2.03
Enterprise Value EBITDA 6.70
Price Book MRQ 1.18

Technical Indicators GLUE

For 52 Weeks

3.50 USD 12.40 USD
50 Day MA 4.53 USD
Shares Short Prior Month 8 872 105
200 Day MA 5.99 USD
Short Ratio 19.34
Shares Short 8 862 358
Short Percent 19.13 %